BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27098532)

  • 1. Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?
    Sangha BS; Nimeiri H; Hickey R; Salem R; Lewandowski RJ
    Curr Treat Options Oncol; 2016 Jun; 17(6):26. PubMed ID: 27098532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
    Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
    BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective internal radiation therapy for liver metastases from colorectal cancer.
    Townsend AR; Chong LC; Karapetis C; Price TJ
    Cancer Treat Rev; 2016 Nov; 50():148-154. PubMed ID: 27690234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 6. Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.
    Virdee PS; Moschandreas J; Gebski V; Love SB; Francis EA; Wasan HS; van Hazel G; Gibbs P; Sharma RA
    JMIR Res Protoc; 2017 Mar; 6(3):e43. PubMed ID: 28351831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases.
    Cercek A; Gendel V; Jabbour S; Moore D; Chen C; Nosher J; Capanu M; Chou JF; Boucher T; Kemeny N; Carpizo DR
    Curr Treat Options Oncol; 2017 Jul; 18(7):42. PubMed ID: 28608276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust evidence for long-term survival with
    Jakobs TF; Paprottka KJ; Raeßler F; Strobl F; Lehner S; Ilhan H; Trumm CG; Fendler WP; Sommer W; Paprottka PM
    Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer.
    Kosmider S; Tan TH; Yip D; Dowling R; Lichtenstein M; Gibbs P
    J Vasc Interv Radiol; 2011 Jun; 22(6):780-6. PubMed ID: 21515072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
    Maleux G; Deroose C; Laenen A; Verslype C; Heye S; Haustermans K; De Hertogh G; Sagaert X; Topal B; Aerts R; Prenen H; Vanbeckevoort D; Vandecaveye V; Van Cutsem E
    Acta Oncol; 2016; 55(4):486-95. PubMed ID: 26625262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
    Mulcahy MF; Mahvash A; Pracht M; Montazeri AH; Bandula S; Martin RCG; Herrmann K; Brown E; Zuckerman D; Wilson G; Kim TY; Weaver A; Ross P; Harris WP; Graham J; Mills J; Yubero Esteban A; Johnson MS; Sofocleous CT; Padia SA; Lewandowski RJ; Garin E; Sinclair P; Salem R;
    J Clin Oncol; 2021 Dec; 39(35):3897-3907. PubMed ID: 34541864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Therasphere Radioembolization for Colorectal Metastases.
    Abbott AM; Kim R; Hoffe SE; Arslan B; Biebel B; Choi J; El-Haddad G; Kis B; Sweeney J; Meredith KL; Almhanna K; Strosberg J; Shibata D; Fulp WJ; Shridhar R
    Clin Colorectal Cancer; 2015 Sep; 14(3):146-53. PubMed ID: 25795047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
    Sharma RA; Van Hazel GA; Morgan B; Berry DP; Blanshard K; Price D; Bower G; Shannon JA; Gibbs P; Steward WP
    J Clin Oncol; 2007 Mar; 25(9):1099-106. PubMed ID: 17369573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?
    Hendlisz A; Sclafani F
    Curr Opin Oncol; 2021 Jul; 33(4):351-352. PubMed ID: 33966002
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization.
    Schonewolf CA; Patel B; Gensure RH; Narra V; Haffty BG; Nosher JL; Jabbour SK
    Am J Clin Oncol; 2014 Jun; 37(3):234-40. PubMed ID: 23275270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer.
    Tohme S; Sukato D; Chalhoub D; McDonald KA; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    Ann Surg Oncol; 2015 May; 22(5):1701-7. PubMed ID: 25190128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
    Salman HS; Cynamon J; Jagust M; Bakal C; Rozenblit A; Kaleya R; Negassa A; Wadler S
    Clin Colorectal Cancer; 2002 Nov; 2(3):173-9. PubMed ID: 12482334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-Based Integration of Yttrium-90 Radioembolization in the Contemporary Management of Hepatic Metastases from Colorectal Cancer.
    Wang DS; Louie JD; Sze DY
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):74-80. PubMed ID: 31079714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.
    Damm R; Seidensticker R; Ulrich G; Breier L; Steffen IG; Seidensticker M; Garlipp B; Mohnike K; Pech M; Amthauer H; Ricke J
    BMC Cancer; 2016 Jul; 16():509. PubMed ID: 27439702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.